186 related articles for article (PubMed ID: 36008229)
1. Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review.
Ramsey ML; Li SS; Lara LF; Gokun Y; Akshintala VS; Conwell DL; Heintz J; Kirkby SE; McCoy KS; Papachristou GI; Patel A; Singh VK; Hart PA
J Cyst Fibros; 2023 Mar; 22(2):193-200. PubMed ID: 36008229
[TBL] [Abstract][Full Text] [Related]
2. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis.
Gould MJ; Smith H; Rayment JH; Machida H; Gonska T; Galante GJ
J Cyst Fibros; 2022 Jul; 21(4):600-602. PubMed ID: 34732308
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis.
Akshintala VS; Kamal A; Faghih M; Cutting GR; Cebotaru L; West NE; Jennings MT; Dezube R; Whitcomb DC; Lechtzin N; Merlo CA; Singh VK
Pancreatology; 2019 Dec; 19(8):1023-1026. PubMed ID: 31611131
[TBL] [Abstract][Full Text] [Related]
4. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
De Boeck K; Weren M; Proesmans M; Kerem E
Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
[TBL] [Abstract][Full Text] [Related]
5. Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis.
Stephenson KG; Lingle AJ; Baumberger KA; Dellon EP; Esther CR; Meier EM; Oermann CM; Shenoy VK; Smith NR; Wimmer NS; Duehlmeyer SR; Kam CW; McKinzie CJ; Poisson MO; Elson EC
J Cyst Fibros; 2023 Nov; 22(6):996-1001. PubMed ID: 37758535
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.
Ooi CY; Durie PR
J Cyst Fibros; 2012 Sep; 11(5):355-62. PubMed ID: 22658665
[TBL] [Abstract][Full Text] [Related]
7. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
[TBL] [Abstract][Full Text] [Related]
8. The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype.
Walkowiak J; Lisowska A; Blaszczyński M
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):157-60. PubMed ID: 18301292
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic complications in children with cystic fibrosis.
Sellers ZM
Curr Opin Pediatr; 2020 Oct; 32(5):661-667. PubMed ID: 32773577
[TBL] [Abstract][Full Text] [Related]
10. Exocrine pancreatic function in cystic fibrosis.
Guy-Crotte O; Carrère J; Figarella C
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):755-9. PubMed ID: 8864671
[TBL] [Abstract][Full Text] [Related]
11. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.
Augarten A; Ben Tov A; Madgar I; Barak A; Akons H; Laufer J; Efrati O; Aviram M; Bentur L; Blau H; Paret G; Wilschanski M; Kerem BS; Yahav Y
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):164-8. PubMed ID: 18301294
[TBL] [Abstract][Full Text] [Related]
12. Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.
Baldwin C; Zerofsky M; Sathe M; Troendle DM; Perito ER
Pancreas; 2019 Aug; 48(7):888-893. PubMed ID: 31268981
[TBL] [Abstract][Full Text] [Related]
13. Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators.
Sadras I; Cohen-Cymberknoh M; Kerem E; Koplewitz BZ; Simanovsky N; Wilschanski M; Birimberg-Schwartz L; Breuer O
J Cyst Fibros; 2023 Jul; 22(4):777-779. PubMed ID: 36914434
[TBL] [Abstract][Full Text] [Related]
14. Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations.
Phadke MY; Sellers ZM
Expert Rev Gastroenterol Hepatol; 2022 Jun; 16(6):499-509. PubMed ID: 35623009
[TBL] [Abstract][Full Text] [Related]
15. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report.
Johns JD; Rowe SM
BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159
[TBL] [Abstract][Full Text] [Related]
16. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
17. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
Munce D; Lim M; Akong K
Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
[TBL] [Abstract][Full Text] [Related]
18. Bicarbonate Transport in Cystic Fibrosis and Pancreatitis.
Angyal D; Bijvelds MJC; Bruno MJ; Peppelenbosch MP; de Jonge HR
Cells; 2021 Dec; 11(1):. PubMed ID: 35011616
[TBL] [Abstract][Full Text] [Related]
19. A proinflammatory, antiapoptotic phenotype underlies the susceptibility to acute pancreatitis in cystic fibrosis transmembrane regulator (-/-) mice.
Dimagno MJ; Lee SH; Hao Y; Zhou SY; McKenna BJ; Owyang C
Gastroenterology; 2005 Aug; 129(2):665-81. PubMed ID: 16083720
[TBL] [Abstract][Full Text] [Related]
20. [Relation between gene mutations and pancreatic exocrine function in patients with cystic fibrosis].
Radivojević D; Guć-Sćekić M; Djurisić M; Lalić T; Minić P; Kanavakis E
Srp Arh Celok Lek; 2001; 129 Suppl 1():6-9. PubMed ID: 15637983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
